ID

21515

Descripción

Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas; ODM derived from: https://clinicaltrials.gov/show/NCT00493454

Link

https://clinicaltrials.gov/show/NCT00493454

Palabras clave

Versiones (1)
  1. 25/04/17 25/04/17 -
Subido en

25 aprile 2017

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Lymphoma NCT00493454

Inglés

Eligibility Lymphoma NCT00493454

1 formularios  
  1. StudyEvent: Eligibility
    1. Eligibility Lymphoma NCT00493454
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. no anti-cancer therapy for three weeks (six weeks if rituximab, nitrosourea or mitomycin c) prior to study initiation, and fully recovered from acute toxicities associated with prior surgery, radiation treatments, chemotherapy, or immunotherapy.
Descripción

cancer treatment | rituximab | Nitrosourea | Mitomycin-c | Toxicity Associated with Operative Surgical Procedures | Toxicity Associated with Therapeutic radiology procedure | Toxicity Associated with Chemotherapy | Toxicity Associated with Immunotherapy | Patient recovered

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0920425
UMLS CUI [2]
C0393022
UMLS CUI [3]
C0028210
UMLS CUI [4]
C0002475
UMLS CUI [5,1]
C0600688
UMLS CUI [5,2]
C0332281
UMLS CUI [5,3]
C0543467
UMLS CUI [6,1]
C0600688
UMLS CUI [6,2]
C0332281
UMLS CUI [6,3]
C1522449
UMLS CUI [7,1]
C0600688
UMLS CUI [7,2]
C0332281
UMLS CUI [7,3]
C0392920
UMLS CUI [8,1]
C0600688
UMLS CUI [8,2]
C0332281
UMLS CUI [8,3]
C0021083
UMLS CUI [9]
C1115804
2. previously treated patients with a histology of refractory/relapsed indolent lymphomas including: (a) extranodal marginal lymphoma of malt type; (b) nodal marginal zone b-cell lymphoma (+/- monocytoid cells); (c) splenic marginal b-cell lymphoma (+/- villous lymphocytes).
Descripción

Patients Treated | Indolent lymphoma refractory | Indolent lymphoma Relapse | Extranodal marginal zone B-cell lymphoma (MALT type) | Monocytoid B-cell lymphoma | Splenic Marginal Zone B-Cell Lymphoma | Splenic Marginal Zone B-Cell Lymphoma Villous Lymphocytes Not Present

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0030705
UMLS CUI [1,2]
C1522326
UMLS CUI [2,1]
C1334170
UMLS CUI [2,2]
C0205269
UMLS CUI [3,1]
C1334170
UMLS CUI [3,2]
C0277556
UMLS CUI [4]
C0852624
UMLS CUI [5]
C0855139
UMLS CUI [6]
C0349632
UMLS CUI [7,1]
C0349632
UMLS CUI [7,2]
C1519987
3. signed informed consent
Descripción

Informed Consent

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0021430
4. age >/= 18 years
Descripción

Age

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0001779
5. expected survival >/= 3 months
Descripción

Life Expectancy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0023671
6. pre-study zubrod performance status of 0, 1, or 2
Descripción

Zubrod Performance Status

Tipo de datos

boolean

Alias
UMLS CUI [1]
C3714786
7. acceptable hematologic status within two weeks prior to patient registration, including: (a) absolute neutrophil count ([segmented neutrophils + bands] * total white blood count (wbc)) >/= 1,500/mm^3; (b) platelet counts >/= 100,000/mm^3.
Descripción

Hematologic function | Absolute neutrophil count | Segmented neutrophil count | Neutrophil Band Cells | Total white blood count | Platelet Count measurement

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0221130
UMLS CUI [2]
C0948762
UMLS CUI [3]
C1168341
UMLS CUI [4]
C3661517
UMLS CUI [5]
C1271681
UMLS CUI [6]
C0032181
8. female patients who are not pregnant or lactating
Descripción

Gender Pregnancy Absent | Gender Breast Feeding Absent

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0079399
UMLS CUI [1,2]
C0032961
UMLS CUI [1,3]
C0332197
UMLS CUI [2,1]
C0079399
UMLS CUI [2,2]
C0006147
UMLS CUI [2,3]
C0332197
9. men and women of reproductive potential who are following accepted birth control methods (as determined by the treating physician)
Descripción

Reproductive potential Contraceptive methods

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C4034483
UMLS CUI [1,2]
C0700589
10. patients previously on phase ii drugs if no long-term toxicity is expected, and the patient has been off the drug for eight or more weeks with no significant post treatment toxicities observed
Descripción

Pharmaceutical Preparations Previous | Toxicity Long-term Unexpected | Pharmaceutical Preparations Discontinued | Toxicity post treatment Absent

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C0205156
UMLS CUI [2,1]
C0600688
UMLS CUI [2,2]
C0443252
UMLS CUI [2,3]
C4055646
UMLS CUI [3,1]
C0013227
UMLS CUI [3,2]
C1444662
UMLS CUI [4,1]
C0600688
UMLS CUI [4,2]
C2709088
UMLS CUI [4,3]
C0332197
11. patients determined to have < 25% bone marrow involvement with lymphoma within six weeks of registration (define measurement of a bone marrow aspirate or biopsy) (this criteria must be strictly met for adequate patient safety.)
Descripción

Lymphoma Bone Marrow Involvement Percentage | Bone marrow aspirate examination | Bone marrow biopsy

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0024299
UMLS CUI [1,2]
C1517677
UMLS CUI [1,3]
C0439165
UMLS CUI [2]
C1271729
UMLS CUI [3]
C0005954
12. patient should have at least one lesion measuring >/= 2 cm in a single dimension.
Descripción

Lesion size Linear Quantity

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0449453
UMLS CUI [1,2]
C0205132
UMLS CUI [1,3]
C1265611
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. prior myeloablative therapies with autologous bone marrow transplantation (abmt) or peripheral blood stem cell (pbsc) rescue.
Descripción

Myeloablative Chemotherapy | Autologous bone marrow transplant | Peripheral Stem Cell Transplantation

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1513784
UMLS CUI [2]
C0194037
UMLS CUI [3]
C0242602
2. platelet count< 100,000 cells/mm^3.
Descripción

Platelet Count measurement

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0032181
3. presence of hypocellular bone marrow.
Descripción

Bone marrow depression

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0151773
4. patients with history of failed stem cell collection.
Descripción

Stem cell collection failed

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C3827940
UMLS CUI [1,2]
C0231175
5. prior radioimmunotherapy
Descripción

Radioimmunotherapy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0085101
6. presence of central nervous system (cns) lymphoma
Descripción

Central nervous system lymphoma

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0742472
7. patients with hiv.
Descripción

HIV Infection

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0019693
8. patients with pleural effusion
Descripción

Pleural effusion

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0032227
9. patients with abnormal liver function: total bilirubin > 2.0 mg/dl
Descripción

Liver Dysfunction | Serum total bilirubin measurement

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0086565
UMLS CUI [2]
C1278039
10. patients with abnormal renal function: serum creatinine > 2.0 mg/dl
Descripción

Abnormal renal function | Creatinine measurement, serum

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0151746
UMLS CUI [2]
C0201976
11. patients who have received prior external beam radiation therapy to > 25% of active bone marrow (involved field or regional)
Descripción

Teleradiotherapy procedure Bone Marrow Percentage

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0419095
UMLS CUI [1,2]
C0005953
UMLS CUI [1,3]
C0439165
12. patients who have received short-acting growth factor support (leukine, neupogen, procrit) within 2 weeks prior to treatment or long-acting growth-factor support (aranesp), neulasta) within 4 weeks prior to treatment.
Descripción

Growth Factor Support Effective short-term | Leukine | Neupogen | Procrit | Growth Factor Support Effective long-term | Aranesp | Neulasta

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0018284
UMLS CUI [1,2]
C0344211
UMLS CUI [1,3]
C1280519
UMLS CUI [1,4]
C0443303
UMLS CUI [2]
C0701500
UMLS CUI [3]
C0733468
UMLS CUI [4]
C0733467
UMLS CUI [5,1]
C0018284
UMLS CUI [5,2]
C0344211
UMLS CUI [5,3]
C1280519
UMLS CUI [5,4]
C0443252
UMLS CUI [6]
C1134440
UMLS CUI [7]
C1171279
13. serious nonmalignant disease or infection which, in the opinion of the investigator and/or the sponsor, would compromise other protocol objectives
Descripción

Disease Serious compromises Protocol Compliance | Communicable Disease Serious compromises Protocol Compliance

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0012634
UMLS CUI [1,2]
C0205404
UMLS CUI [1,3]
C2945640
UMLS CUI [1,4]
C0525058
UMLS CUI [2,1]
C0009450
UMLS CUI [2,2]
C0205404
UMLS CUI [2,3]
C2945640
UMLS CUI [2,4]
C0525058
14. major surgery, other than diagnostic surgery, within four weeks
Descripción

major surgery | Diagnostic surgical procedure

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0679637
UMLS CUI [2]
C0522769
15. evidence of transformation in the latest biopsy
Descripción

Cell transformation Evidence Biopsy

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0040682
UMLS CUI [1,2]
C3887511
UMLS CUI [1,3]
C0005558
Volver a la parte superior de la página

Similar models

Eligibility Lymphoma NCT00493454

1 formularios
  1. StudyEvent: Eligibility
    1. Eligibility Lymphoma NCT00493454
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
cancer treatment | rituximab | Nitrosourea | Mitomycin-c | Toxicity Associated with Operative Surgical Procedures | Toxicity Associated with Therapeutic radiology procedure | Toxicity Associated with Chemotherapy | Toxicity Associated with Immunotherapy | Patient recovered
Item
1. no anti-cancer therapy for three weeks (six weeks if rituximab, nitrosourea or mitomycin c) prior to study initiation, and fully recovered from acute toxicities associated with prior surgery, radiation treatments, chemotherapy, or immunotherapy.
boolean
C0920425 (UMLS CUI [1])
C0393022 (UMLS CUI [2])
C0028210 (UMLS CUI [3])
C0002475 (UMLS CUI [4])
C0600688 (UMLS CUI [5,1])
C0332281 (UMLS CUI [5,2])
C0543467 (UMLS CUI [5,3])
C0600688 (UMLS CUI [6,1])
C0332281 (UMLS CUI [6,2])
C1522449 (UMLS CUI [6,3])
C0600688 (UMLS CUI [7,1])
C0332281 (UMLS CUI [7,2])
C0392920 (UMLS CUI [7,3])
C0600688 (UMLS CUI [8,1])
C0332281 (UMLS CUI [8,2])
C0021083 (UMLS CUI [8,3])
C1115804 (UMLS CUI [9])
Patients Treated | Indolent lymphoma refractory | Indolent lymphoma Relapse | Extranodal marginal zone B-cell lymphoma (MALT type) | Monocytoid B-cell lymphoma | Splenic Marginal Zone B-Cell Lymphoma | Splenic Marginal Zone B-Cell Lymphoma Villous Lymphocytes Not Present
Item
2. previously treated patients with a histology of refractory/relapsed indolent lymphomas including: (a) extranodal marginal lymphoma of malt type; (b) nodal marginal zone b-cell lymphoma (+/- monocytoid cells); (c) splenic marginal b-cell lymphoma (+/- villous lymphocytes).
boolean
C0030705 (UMLS CUI [1,1])
C1522326 (UMLS CUI [1,2])
C1334170 (UMLS CUI [2,1])
C0205269 (UMLS CUI [2,2])
C1334170 (UMLS CUI [3,1])
C0277556 (UMLS CUI [3,2])
C0852624 (UMLS CUI [4])
C0855139 (UMLS CUI [5])
C0349632 (UMLS CUI [6])
C0349632 (UMLS CUI [7,1])
C1519987 (UMLS CUI [7,2])
Informed Consent
Item
3. signed informed consent
boolean
C0021430 (UMLS CUI [1])
Age
Item
4. age >/= 18 years
boolean
C0001779 (UMLS CUI [1])
Life Expectancy
Item
5. expected survival >/= 3 months
boolean
C0023671 (UMLS CUI [1])
Zubrod Performance Status
Item
6. pre-study zubrod performance status of 0, 1, or 2
boolean
C3714786 (UMLS CUI [1])
Hematologic function | Absolute neutrophil count | Segmented neutrophil count | Neutrophil Band Cells | Total white blood count | Platelet Count measurement
Item
7. acceptable hematologic status within two weeks prior to patient registration, including: (a) absolute neutrophil count ([segmented neutrophils + bands] * total white blood count (wbc)) >/= 1,500/mm^3; (b) platelet counts >/= 100,000/mm^3.
boolean
C0221130 (UMLS CUI [1])
C0948762 (UMLS CUI [2])
C1168341 (UMLS CUI [3])
C3661517 (UMLS CUI [4])
C1271681 (UMLS CUI [5])
C0032181 (UMLS CUI [6])
Gender Pregnancy Absent | Gender Breast Feeding Absent
Item
8. female patients who are not pregnant or lactating
boolean
C0079399 (UMLS CUI [1,1])
C0032961 (UMLS CUI [1,2])
C0332197 (UMLS CUI [1,3])
C0079399 (UMLS CUI [2,1])
C0006147 (UMLS CUI [2,2])
C0332197 (UMLS CUI [2,3])
Reproductive potential Contraceptive methods
Item
9. men and women of reproductive potential who are following accepted birth control methods (as determined by the treating physician)
boolean
C4034483 (UMLS CUI [1,1])
C0700589 (UMLS CUI [1,2])
Pharmaceutical Preparations Previous | Toxicity Long-term Unexpected | Pharmaceutical Preparations Discontinued | Toxicity post treatment Absent
Item
10. patients previously on phase ii drugs if no long-term toxicity is expected, and the patient has been off the drug for eight or more weeks with no significant post treatment toxicities observed
boolean
C0013227 (UMLS CUI [1,1])
C0205156 (UMLS CUI [1,2])
C0600688 (UMLS CUI [2,1])
C0443252 (UMLS CUI [2,2])
C4055646 (UMLS CUI [2,3])
C0013227 (UMLS CUI [3,1])
C1444662 (UMLS CUI [3,2])
C0600688 (UMLS CUI [4,1])
C2709088 (UMLS CUI [4,2])
C0332197 (UMLS CUI [4,3])
Lymphoma Bone Marrow Involvement Percentage | Bone marrow aspirate examination | Bone marrow biopsy
Item
11. patients determined to have < 25% bone marrow involvement with lymphoma within six weeks of registration (define measurement of a bone marrow aspirate or biopsy) (this criteria must be strictly met for adequate patient safety.)
boolean
C0024299 (UMLS CUI [1,1])
C1517677 (UMLS CUI [1,2])
C0439165 (UMLS CUI [1,3])
C1271729 (UMLS CUI [2])
C0005954 (UMLS CUI [3])
Lesion size Linear Quantity
Item
12. patient should have at least one lesion measuring >/= 2 cm in a single dimension.
boolean
C0449453 (UMLS CUI [1,1])
C0205132 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
Item Group
C0680251 (UMLS CUI)
Myeloablative Chemotherapy | Autologous bone marrow transplant | Peripheral Stem Cell Transplantation
Item
1. prior myeloablative therapies with autologous bone marrow transplantation (abmt) or peripheral blood stem cell (pbsc) rescue.
boolean
C1513784 (UMLS CUI [1])
C0194037 (UMLS CUI [2])
C0242602 (UMLS CUI [3])
Platelet Count measurement
Item
2. platelet count< 100,000 cells/mm^3.
boolean
C0032181 (UMLS CUI [1])
Bone marrow depression
Item
3. presence of hypocellular bone marrow.
boolean
C0151773 (UMLS CUI [1])
Stem cell collection failed
Item
4. patients with history of failed stem cell collection.
boolean
C3827940 (UMLS CUI [1,1])
C0231175 (UMLS CUI [1,2])
Radioimmunotherapy
Item
5. prior radioimmunotherapy
boolean
C0085101 (UMLS CUI [1])
Central nervous system lymphoma
Item
6. presence of central nervous system (cns) lymphoma
boolean
C0742472 (UMLS CUI [1])
HIV Infection
Item
7. patients with hiv.
boolean
C0019693 (UMLS CUI [1])
Pleural effusion
Item
8. patients with pleural effusion
boolean
C0032227 (UMLS CUI [1])
Liver Dysfunction | Serum total bilirubin measurement
Item
9. patients with abnormal liver function: total bilirubin > 2.0 mg/dl
boolean
C0086565 (UMLS CUI [1])
C1278039 (UMLS CUI [2])
Abnormal renal function | Creatinine measurement, serum
Item
10. patients with abnormal renal function: serum creatinine > 2.0 mg/dl
boolean
C0151746 (UMLS CUI [1])
C0201976 (UMLS CUI [2])
Teleradiotherapy procedure Bone Marrow Percentage
Item
11. patients who have received prior external beam radiation therapy to > 25% of active bone marrow (involved field or regional)
boolean
C0419095 (UMLS CUI [1,1])
C0005953 (UMLS CUI [1,2])
C0439165 (UMLS CUI [1,3])
Growth Factor Support Effective short-term | Leukine | Neupogen | Procrit | Growth Factor Support Effective long-term | Aranesp | Neulasta
Item
12. patients who have received short-acting growth factor support (leukine, neupogen, procrit) within 2 weeks prior to treatment or long-acting growth-factor support (aranesp), neulasta) within 4 weeks prior to treatment.
boolean
C0018284 (UMLS CUI [1,1])
C0344211 (UMLS CUI [1,2])
C1280519 (UMLS CUI [1,3])
C0443303 (UMLS CUI [1,4])
C0701500 (UMLS CUI [2])
C0733468 (UMLS CUI [3])
C0733467 (UMLS CUI [4])
C0018284 (UMLS CUI [5,1])
C0344211 (UMLS CUI [5,2])
C1280519 (UMLS CUI [5,3])
C0443252 (UMLS CUI [5,4])
C1134440 (UMLS CUI [6])
C1171279 (UMLS CUI [7])
Disease Serious compromises Protocol Compliance | Communicable Disease Serious compromises Protocol Compliance
Item
13. serious nonmalignant disease or infection which, in the opinion of the investigator and/or the sponsor, would compromise other protocol objectives
boolean
C0012634 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
C2945640 (UMLS CUI [1,3])
C0525058 (UMLS CUI [1,4])
C0009450 (UMLS CUI [2,1])
C0205404 (UMLS CUI [2,2])
C2945640 (UMLS CUI [2,3])
C0525058 (UMLS CUI [2,4])
major surgery | Diagnostic surgical procedure
Item
14. major surgery, other than diagnostic surgery, within four weeks
boolean
C0679637 (UMLS CUI [1])
C0522769 (UMLS CUI [2])
Cell transformation Evidence Biopsy
Item
15. evidence of transformation in the latest biopsy
boolean
C0040682 (UMLS CUI [1,1])
C3887511 (UMLS CUI [1,2])
C0005558 (UMLS CUI [1,3])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial